Baxter second-quarter earnings rose to $544 million, up 26 percent from the same period last year, helped by strong demand for its treatments for haemophilia and other immune disorders.

The company's BioScience unit posted quarterly revenue growth of 16 percent to $1.4 billion, with non-US sales accounting for $795 million, a jump of 21 percent over the prior-year period. Morningstar analyst Julie Stralow stated that "every quarter it's a similar story: BioScience leads growth, mix and pricing leads to increased margins and allows for greater R&D."